Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient.

Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. Clin Lymphoma Myeloma Leuk. 2014 Feb 4; Authors: Broccoli A, Pellegrini C, Celli M, Argnani L, Agostinelli C, Pileri S, Zinzani PL PMID: 24629851 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Related Links:

Authors: Zi F, Yu L, Shi Q, Tang A, Cheng J Abstract B-cell receptor (BCR) signaling is important for the development and maturation of normal B-cells and plays a key role in B-cell malignancies. Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in BCR signaling, has emerged as an attractive target and has been successfully applied in the treatment of hematological malignancies. Ibrutinib, a BTK inhibitor, has demonstrated marked efficacy and tolerability in treatment-naïve, relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). Ibru...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Luo Huang, Yongzhong Wu, Ying Wang, Yue Xie, Furong Wu, Shujie Li, Zhongguo Liang, Xiaodong ZhuAbstractThe aim of this study is to develop a prognostic nomogram for early stage extranodal NK/T-cell lymphoma, nasal-type (ENKL) treated with high-dose radiotherapy (RT). A total of 81 patients at two cancer centers with stage I to IIE ENKL who received chemotherapy (CT) and high-dose RT were retrospectively analyzed. The 5-year OS rate and PFS were 64.7% and 57.5% respectively for the entire group. The development of the ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Daniella Klebaner, Divya Koura, Dimitrios Tzachanis, Edward D. Ball, Steven Horwitz, Aaron M. GoodmanAbstractHepatosplenic T-cell Lymphoma (HSTCL) is a rare peripheral T-cell lymphoma that disproportionately affects individuals with a clinical history of immunosuppression. It carries a poor prognosis, and due to its rarity, there is no single or well-established treatment.We conducted the largest-to-date individual-level meta-analysis based on literature searches to determine the best induction therapy for HSTCL. We c...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The aim of this study is to develop a prognostic nomogram for early stage extranodal NK/T-cell lymphoma, nasal-type (ENKL) treated with high-dose radiotherapy (RT). A total of 81 patients at two cancer centers with stage I to IIE ENKL who received chemotherapy (CT) and high-dose RT were retrospectively analyzed. The 5-year OS rate and PFS were 64.7% and 57.5% respectively for the entire group. The development of the nomogram was based on the Cox proportional hazards model. We have implemented the concordance index (C-index) and performed a calibration curve to determine its predictive and discriminatory capacity and compar...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Hepatosplenic T-cell Lymphoma (HSTCL) is a rare peripheral T-cell lymphoma that disproportionately affects individuals with a clinical history of immunosuppression. It carries a poor prognosis, and due to its rarity, there is no single or well-established treatment.We conducted the largest-to-date individual-level meta-analysis based on literature searches to determine the best induction therapy for HSTCL. We compared response rates and survival among patients who received “non-CHOP-based” induction with regimens containing cytarabine, etoposide, and/or platinum-based treatment to those receiving treatment with...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
The impact of epigenetic regulations on myeloma cells is attracting more and more attention. Chidamide, a novel histone deacetylase inhibitor (HDACi) independently developed in China, has been approved for the treatment of T cell lymphoma. Yet its action on myeloma is not elucidated. We previously found that ASH2L gene, which enhanced the activity of oncogene methyltransferase, was highly expressed in some patients with multiple myeloma (MM). The main purpose of this study is to investigate the anti-myeloma effects of Chidamide and ASH2L involvement.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Authors: Huang W, Cao Z, Zeng L, Guo L, Liu X, Lv N, Feng X Abstract Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is an aggressive lymphoma associated with a poor outcome. To date, the factor consistently associated with prognosis is the International Prognostic Index (IPI) score; however, it is considered that the IPI score cannot be beneficial for guiding potential targeted therapies. New scoring systems have recently been developed. The aim of the present study was to observe the expression of NME/NM23 nucleoside diphosphate kinase 1 (nm23), nuclear DNA topoisomerase 2-α (TOP2A), multiple ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Peripheral T cell lymphomas represent a minority of all non-Hodgkin lymphomas and share an overall unfavorable outcome following standard anthracycline-based chemotherapy. Brentuximab vedotin (BV) is an anti-CD30-specific antibody-drug conjugate that has largely proved to be safe and effective in the treatment of these diseases. However, data regarding its use in patients with chronic kidney disease are limited. Here we present the first real life experience of BV administered to a patient undergoing hemodialysis (HD), with successful results in terms of both efficacy and safety.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Brentuximab vedotin (BV), an anti-CD30-specific antibody-drug conjugate (ADC), is one of the most promising new agents employed in the treatment of peripheral T-cell lymphomas (PTCLs), in particular, systemic anaplastic large cell lymphomas (sALCL).1,2 The drug has proved to be safe and effective both as a single agent in relapsed/refractory disease and in combination with standard chemotherapy in the first-line setting.3-7
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Publication date: Available online 29 May 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Katharine L. Lewis, Dominic Spagnolo, Dejan Radeski, Chan Yoon Cheah
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Broccoli | Cancer & Oncology | Lymphoma | Myeloma | Revlimid | T-cell Lymphoma